Life Sciences Summit Speakers

Lisa DYson, PhD

CEO @ Air Protein

 

Neil Dhawan

CEO & Co-Founder @ Totus Medicines

 

Steve Meller

Ceo @ CH4 Global

     

Philip Johnson

SVP and Treasurer- Finance/Proc/GBS/ Strategy @ Eli Lilly

   

Jason Pontin

Partner @ DCVC

David Berry

GP @ Flagship Pioneering

 

Kiersten Stead

Managing Partner @ DCVC Bio

 

Brad Robling

VP @ Lilly New Ventures

     

Life Sciences Summit Agenda

1pm ET – Dec 9, 2021

This event is by invitation only.

Request Invitation

December 9, 2021

1:00pm – 1:10pm ET

Introduction

Hosts BVCC & DCVC will introduce the summit council, partners and fundamental goals.

1:10pm – 1:35pm ET

Dr. Kiersten Stead of DCVC Bio

Trends and investment opportunities in Life Sciences

 a. Mapping out the Life Sciences industry (technology & investing)
-Whats Feasible (Dominos have already fallen)
-Whats on the cusp
-Whats still in the future
b. Q&A

1:35pm – 1:55pm ET

David Berry, GP of Flagship Pioneering

Overview of unique innovation process

1:55pm – 2:30pm ET

Jason Pontin of DCVC

Investment sizes, what VC funds look for and how they analyze startup companies in Life Sciences at different stages of development (pre-seed, seed, Series A, Series B).
a. IP development
b. Product development
c. Product market fit and customer traction
d. Size of total addressable market (TAM) and Elastic
e. Vast majority of companies are not VC backable (but those are still viable businesses…component company, etc) (backable means can get there with $100mm and huge TAM and 10 to 100x)
f. 2 case studies investing in Life Science tech startups

2:30pm – 3:00pm ET

Dr. Lisa Dyson of Air Protein 

Opportunities and challenges regarding startups in the Life Science industry

3:00pm – 3:10pm ET

Break

10 Min 

3:10pm – 3:40pm ET

Brad Robling & Philip Johnson of Eli Lilly – Strategic Speakers

Strategic perspective – What would they buy, or look for in a supplier in the Life Science industry.

3:40pm – 4:20pm ET

CH4 Global Inc – Steve Meller, CEO

a. Overview of company
b. IP/Product description
c. Customer profile/s and use case/s
d. Problem that company is trying to solve
i. the nature of the problem
ii. unsuccessful methods attempted in the past to solve the problem
iii. potential solutions/new approaches
e. Q & A

4:20pm – 5:00pm ET

Totus Medicines – Neil Dhawan, CEO

a. Overview of company
b. IP/Product description
c. Customer profile/s and use case/s
d. Problem that company is trying to solve
i. the nature of the problem
ii. unsuccessful methods attempted in the past to solve the problem
iii. potential solutions/new approaches
e. Q & A

5:00pm ET

Happy Hour / Networking

Gather.Town